Leqembi gains approval for Alzheimer’s treatment in Israel
The approval of Leqembi (generic name: Lecanemab) in Israel marks a significant milestone, as Israel becomes the sixth territory to endorse the drug for Alzheimer’s treatment after the
These treatments, known as Folding Interfering Degraders (FIDs), target the protein folding process to induce the degradation of cancer-related proteins. The collaboration will leverage Sibylla’s Pharmacological Protein Inactivation